guanabenz has been researched along with Amyotrophic Lateral Sclerosis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Abbott, BM; Browne, EC | 1 |
| Abgueguen, E; Antonini, G; Bersano, E; Borghero, G; Capasso, M; Caponnetto, C; Chiò, A; Corbo, M; Dalla Bella, E; Filosto, M; Furlan, R; Giannini, F; Lauria, G; Lunetta, C; Mandrioli, J; Messina, S; Monsurrò, MR; Mora, G; Nolan, JM; Riva, N; Rizzi, R; Siciliano, G; Silani, V; Simone, I; Sorarù, G; Spataro, R; Tramacere, I; Tugnoli, V; Verriello, L; Volanti, P | 1 |
| Antonini, G; Bella, ED; Bella, V; Borghero, G; Capasso, M; Caponnetto, C; Chiò, A; Corbo, M; Eleopra, R; Filosto, M; Giannini, F; Granieri, E; Lauria, G; Lunetta, C; Mandrioli, J; Mazzini, L; Messina, S; Monsurrò, MR; Mora, G; Riva, N; Rizzi, R; Siciliano, G; Silani, V; Simone, I; Sorarù, G; Tramacere, I; Volanti, P | 1 |
| Feng, HL; Jiang, HQ; Jiang, HZ; Qi, Y; Ren, M; Wang, J; Wang, SY; Wang, XD; Yin, X; Zhang, J | 1 |
| Popko, B; Roos, RP; Tixier, E; Wang, L | 1 |
| Barry, N; Bertolotti, A; D'Antonio, M; Das, I; Krzyzosiak, A; Schneider, K; Sigurdardottir, A; Wrabetz, L | 1 |
| De Zutter, GS; Gill, A; Hatzipetros, T; Jiang, B; Kidd, JD; Levine, B; Lincecum, JM; Moreno, AJ; Perrin, S; Ping, Q; Tassinari, VR; Thompson, K; Vieira, FG; Wang, MZ | 1 |
1 review(s) available for guanabenz and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Recent progress towards an effective treatment of amyotrophic lateral sclerosis using the SOD1 mouse model in a preclinical setting.
Topics: Amyotrophic Lateral Sclerosis; Animals; Biological Products; Disease Models, Animal; Drug Discovery; Humans; Mice; Superoxide Dismutase-1 | 2016 |
2 trial(s) available for guanabenz and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
The unfolded protein response in amyotrophic later sclerosis: results of a phase 2 trial.
Topics: Adrenergic alpha-2 Receptor Agonists; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Female; Guanabenz; Humans; Male; Middle Aged; Unfolded Protein Response | 2021 |
Protein misfolding, amyotrophic lateral sclerosis and guanabenz: protocol for a phase II RCT with futility design (ProMISe trial).
Topics: Adrenergic alpha-2 Receptor Agonists; Age of Onset; Amyotrophic Lateral Sclerosis; Disease Progression; Double-Blind Method; Endoplasmic Reticulum Stress; Guanabenz; Humans; Italy; Medical Futility; Neuroprotective Agents; Proteostasis Deficiencies | 2017 |
4 other study(ies) available for guanabenz and Amyotrophic Lateral Sclerosis
| Article | Year |
|---|---|
Guanabenz delays the onset of disease symptoms, extends lifespan, improves motor performance and attenuates motor neuron loss in the SOD1 G93A mouse model of amyotrophic lateral sclerosis.
Topics: Age of Onset; Amyotrophic Lateral Sclerosis; Animals; Cell Death; Disease Models, Animal; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Female; Guanabenz; Mice, Transgenic; Mitochondria; Motor Activity; Motor Neurons; Nerve Degeneration; Neuroprotective Agents; Random Allocation; Superoxide Dismutase; Survival Analysis | 2014 |
Guanabenz, which enhances the unfolded protein response, ameliorates mutant SOD1-induced amyotrophic lateral sclerosis.
Topics: Age Factors; Amyotrophic Lateral Sclerosis; Animals; Calcium-Binding Proteins; Cytokines; Disease Models, Animal; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Guanabenz; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microfilament Proteins; Protein Unfolding; Superoxide Dismutase; Survival Analysis | 2014 |
Preventing proteostasis diseases by selective inhibition of a phosphatase regulatory subunit.
Topics: Amyotrophic Lateral Sclerosis; Animals; Cells, Cultured; Charcot-Marie-Tooth Disease; Disease Models, Animal; Endoplasmic Reticulum Stress; Enzyme Inhibitors; Guanabenz; HeLa Cells; Humans; Mice; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Folding; Protein Phosphatase 1; Proteostasis Deficiencies; Signal Transduction | 2015 |
Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS.
Topics: Adrenergic alpha-2 Receptor Agonists; Amyotrophic Lateral Sclerosis; Animals; Antihypertensive Agents; Disease Models, Animal; Disease Progression; eIF-2 Kinase; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factor-2; Fibroblasts; Guanabenz; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nerve Degeneration; Phosphorylation; Protein Phosphatase 1; Superoxide Dismutase; Tunicamycin; Unfolded Protein Response | 2015 |